Engineering chimeric antigen receptor T cell signals to generate effective anti-tumour responses [ 2019 - ]

Research Grant

Brief description Immunotherapy using genetically engineered killer cells, redirected towards a patients tumour, has revolutionised the way we treat cancer. While these treatments have been very effective, they are not without side effects. This study will enable the design of tailored and safe immunotherapy treatments so that immune responses can be tailored to the tumour type. This research will help design better therapies for cancer patients.

Funding Amount $472,127.00

Funding Scheme Project Grants

Notes Standard Project Grant